Skip to main content

Table 2 Cumulative incidences of mortality of patients

From: Effect of prior cancer on survival outcomes for patients with pancreatic adenocarcinoma: a propensity score analysis

Cancer type No Cancer-specific mortality (%) p a Non-cancer-specific mortality (%) p a
1-year (95% CI) 2-year (95% CI) 3-year (95% CI) 1-year (95% CI) 2-year (95% CI) 3-year (95% CI)
Whole cohort 9235 60.6(60.5–60.7) 77.8(77.9–77.8) 84.4(84.3–84.5)   2.7(2.6–2.8) 3.5(3.4–3.6) 3.8(3.7–3.9)  
Without prior cancer 8797 60.9(60.8–70.0) 78.2(78.1–78.3) 84.9(84.8–85.0)   2.3(2.2–2.4) 3.0(2.9–3.1) 3.3(3.2–3.4)  
Prostate cancer 126 59.5(59.1–59.9) 69.6(69.3–70.0) 80.8(80.5–81.1) 0.237 9.1(9.0–9.2) 12.1(11.9–12.3) 12.1(11.9–12.3) < 0.001
Breast cancer 110 62.4(61.9–62.9) 78.6(78.1–79.1) 84.7(84.2–85.2) 0.029 5.8(5.6–6.0) 8.3(8.1–8.5) 8.3(8.1–8.5) < 0.001
Renal and bladder cancer 51 52.2(51.1–53.3) 64.1(63.1–65.1) 72.1(71.0–73.1) 0.067 12.2(11.2–13.2) 14.6(13.6–15.6) 14.6(13.6–15.6) < 0.001
Colon and rectal cancer 43 60.5(59.3–61.6) 75.4(74.5–76.3) 78.4(77.5–79.3) 0.746 9.3(8.9–9.7) 9.3(8.9–9.7) 9.3(8.9–9.7) 0.033
Uterine cancer 24 49.4(47.0–51.8) 54.6(52.2–57.1) 54.6(52.2–57.1) 0.063 8.8(8.1–9.6) 8.8(8.1–9.6) 8.8(8.1–9.6) 0.096
Lung cancer 16 38.8(36.1–41.5) 73.1(68.9–77.3) 73.1(68.9–77.3) 0.017 13.1(10.6–15.6) 13.1(10.6–15.6) 13.1(9.1–17.1) < 0.001
Small intestinal cancer 15 42.0(38.2–45.8) 53.7(36.6–67.4) NA 0.076 14.0(12.1–15.9) 34.5(28.7–40.4) NA < 0.001
Oral cancer 13 40.4(36.1–44.7) 75.0(71.1–78.9) NA 0.456 7.7(6.5–8.9) 7.7(6.5–8.9) NA 0.008
Gastric cancer 12 53.8(48.0–59.6) 90.3(76.7-) NA 0.985 9.7(7.7–11.7) 9.7(7.7–11.7) NA 0.204
Hepatocellular cancer 8 50.0(42.3–57.7) 62.5(54.2–70.8) 62.5(54.2–70.8) 0.217 12.5(9.4–15.6) 25.0(18.9–31.1) 25.0(18.9–31.1) < 0.001
Matched cohort 4818 61.8(61.7–61.9) 77.7(77.6–77.8) 83.8(83.7–83.9)   3.1(3.0–3.2) 4.1(4.0–4.2) 4.5(4.4–4.6)  
Without prior cancer 4380 62.4(62.3–62.5) 78.6(78.6–84.7) 84.7(84.5–84.8)   2.4(2.3–2.5) 3.2(3.1–3.3) 3.6(3.5–3.7)  
Prostate cancer 126 59.5(59.1–59.9) 69.6(69.3–70.0) 80.8(80.5–81.1) 0.173 9.1(9.0–9.2) 12.1(11.9–12.3) 12.1(11.9–12.3) < 0.001
Breast cancer 110 62.4(61.9–62.9) 78.6(78.1–79.1) 84.7(84.2–85.2) 0.074 5.8(5.6–6.0) 8.3(8.1–8.5) 8.3(8.1–8.5) 0.001
Renal and bladder cancer 51 52.2(51.1–53.3) 64.1(63.1–65.1) 72.1(71.0–73.1) 0.051 12.2(11.2–13.2) 14.6(13.6–15.6) 14.6(13.6–15.6) < 0.001
Colon and rectal cancer 43 60.5(59.3–61.6) 75.4(74.5–6.3) 78.4(77.5–79.3) 0.654 9.3(8.9–9.7) 9.3(8.9–9.7) 9.3(8.9–9.7) 0.058
Uterine cancer 24 49.4(47.0–51.8) 54.6(52.2–57.1) 54.6(52.2–57.1) 0.051 8.8(8.1–9.6) 8.8(8.1–9.6) 8.8(8.1–9.6) 0.123
Lung cancer 16 38.8(36.1–41.5) 73.1(68.9–77.3) 73.1(68.9–77.3) 0.215 13.1(10.6–15.6) 13.1(10.6–15.6) 13.1(9.1–17.1) 0.052
Small intestinal cancer 15 42.0(38.2–45.8) 53.7(36.6–47.4) NA 0.065 14.0(12.1–15.9) 34.5(28.7–40.4) NA < 0.001
Oral cancer 13 40.4(36.1–44.7) 75.0(71.1–78.9) NA 0.412 7.7(6.5–8.9) 7.7(6.5–8.9) NA 0.013
Gastric cancer 12 53.8(48.0–59.6) 90.3(76.7-) NA 0.922 9.7(7.7–11.7) 9.7(7.7–11.7) NA 0.238
Hepatocellular cancer 8 50.0(42.3–57.7) 62.5(54.2–70.8) 62.5(54.2–70.8) 0.207 12.5(9.4–15.6) 25.0(18.9–31.1) 25.0(18.9–31.1) 0.001
  1. NA Not available, CI Confidence interval
  2. pa-values represented the differences of cancer-specific mortalities or non-cancer-specific mortalities between patients with certain kind of prior tumor and those without prior tumor